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A R T I C L E   I N F O S U M M A R Y 
A Combination of 0.3mg/kg buprenorphine and 1.0 mg/kg naltrexone treatment 
shows a promising result due to its ability to attenuate reinstatement (relapse) in 
morphine/methamphetamine (polydrug)-dependent mice in a conditioned place 
preference (CPP) model. This prompted us to identify which opioid receptor that 
contributes to its anti-relapse activity. Using the same CPP model, 10 mg/kg nor- 
BNI (a selective kappa opioid receptor [KOR] antagonist) was used to evaluate the 
involvement of KOR in mediating relapse to polydrug dependence. By applying the 
immunohistochemistry (IHC) technique, the investigation was extended to the mice 
brain using KOR antibody (EPR18881), focusing on the brain regions that are 
abundant in KOR density. The results showed that nor-BNI alone failed to attenuate 
relapse to polydrug dependence. However, the IHC results proved that the number 
of KOR significantly increased in the striatum during reinstatement compared to 
post-conditioning (p <0.05). The KOR was significantly suppressed in the treatment 
group which strengthens the findings from previous studies proving that the KOR 
plays an important role in mediating relapse to polydrug dependence. 
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INTRODUCTION 
The kappa opioid receptor (KOR) has been associated 
with relapse to many drugs of abuse. Therefore, this 
receptor may be used as a potential target to prevent 
relapse to drug taking, which includes polydrugs 
(Wee 2012). This study aims to investigate the distinct 
role of KOR in mediating relapse to morphine/ 
methamphetamine (polydrug dependence) at 
behavioral and brain level. 
MATERIALS AND METHODS 
All experiments were conducted using adult male 
Swiss albino mice weighing around 25 – 35 g (8 – 10 
weeks old). The experimental protocols were 
approved by the IIUM’s Institutional Animal Care 
and Use Committee (IACUC).  
In a three-compartment CPP model, the mice were 
made dependent on 7.52 mg/kg morphine and 1.0 
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mg/kg methamphetamine during the conditioning 
phase. After successful extinction, and prior to 
reinstatement, the mice received either the treatment 
(a combination of 0.3 mg/kg buprenorphine/1.0 
mg/kg naltrexone), a selective KOR antagonist (10 
mg/kg nor-BNI), or saline (control).  
The brain tissues were harvested and processed after 
the behavioral experiment was completed. The rabbit 
monoclonal to KOR antibody (EPR18881) was used to 
identify the KOR at four different brain regions 
(amygdala, hippocampus, prefrontal cortex and 
striatum). All data were statistically analysed using a 
paired-samples t-test. 
RESULTS AND DISCUSSION 
Polydrug dependence was significantly seen to have 
developed in all three groups (p < 0.001) in 
comparison to their own baseline. A non-significant 
reinstatement to polydrug was observed with 19.29± 
14.32% preference towards the drug-paired 
compartment (n=13) in the treatment group, where 
reinstatement was successfully attenuated in 6 mice 
that did not develop stereotyped behaviour. The non- 
significant polydrug reinstatement was proven not to 
be caused by KOR antagonism, since nor-BNI itself 
failed to attenuate reinstatement to polydrug 
dependence. 
 
Further investigation done using IHC technique 
proved that the dose of naltrexone used successfully 
suppressed KOR expression in all brain regions 
studied. It was discovered that the number of KOR 
significantly increased in the striatum during the 
reinstatement (relapse) phase compared to post-
conditioning (33.39 ± 5.60 and 16.73 ± 5.26 
respectively, p <0.05) and also markedly increased in 
the hippocampus (65.25 ± 4.13 and 51.11 ± 6.87 
respectively) in the control (saline) group. 
 
The hyperactivity of KOR system has been linked to 
dysphoria which leads to drug relapse (Gerra, 2006). 
The increase of KOR in the striatum and hippocampus 
suggests that polydrug withdrawal truly affects the 
KOR system. These two brain regions have a high 
density of KOR (Zhou 2015). Therefore, it is believed 
that the suppression of this receptor might prevent 
drug relapse, including to polydrugs which has been 
shown by the IHC results where the KOR expression 
was significantly suppressed in all the four brain 
regions. 
 
Fig. 1. CPP test for morphine/methamphetamine- 
conditioned (polydrug) (saline [control]) (n = 11), 
buprenorphine/naltrexone [Bup/Ntx] [treatment] (n = 13) 
and nor-BNI groups (n = 10). ** indicates a very 
significant difference (p < 0.01) from baseline and *** 




Although there are conflicting evidence suggesting 
the activation of KOR system is the key to prevent 
relapse to drug taking, this study prove that number 
of KOR increase during reinstatement.  The mice that 
response well to buprenorphine/naltrexone 
treatment has no expression of KOR, suggest that 
KOR system can be manipulated to treat polydrug 
dependence. 
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